Compare Medpace Holdings Inc (MEDP) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs US Bancorp — how do they compare? Medpace Holdings Inc trades at $617.27 (market cap $16.82B), while US Bancorp trades at $56.63 (market cap $88.86B). The key difference: US Bancorp is far larger — about 5.3× Medpace Holdings Inc's market cap, and US Bancorp pays a 3.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and US Bancorp for 97 Days on average.
| MEDP | USB | |
|---|---|---|
Market Cap | $16.82B | $88.86B |
Volume | 223,093 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $630.19 | $65.42 |
52-Week Low | $393.42 | $45.28 |
Typical Hold Time | 14 Days | 97 Days |
Enterprise Value | $16.44B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
U.S. Bancorp (USB) trades at $56.17, down 1.95% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock offers a $2.16 annual dividend yield with recent 3.8% increase. Analyst consensus is bullish with $69.94 price target despite near-term technical weakness.
USB presents a value opportunity with attractive P/E of 11.38 and strong profitability metrics, though investors face interest rate sensitivity and regulatory uncertainty risks. The bank's solid earnings track record and dividend growth support long-term investment case despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
